{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006955",
      "entity_text" : "immune response",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:23725625",
      "entity_text" : "olaparib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The findings that an antitumor immune response is elicited by olaparib in Brca1 deficient tumors prompted us to assess tumor infiltrating immune cells in PBM bearing mice upon treatment.",
  "reading_complete" : "2020-08-08T07:39:56Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T07:37:30Z",
  "trigger" : "elicited",
  "evidence" : [ "immune response is elicited by olaparib" ],
  "pmc_id" : "6366450",
  "score" : 0
}